2. Search Result
Search Result
Results for "

LDLc

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

3

Inhibitory Antibodies

2

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99552
    Tafolecimab

    IBI-306

    		 PCSK9 Cardiovascular Disease
    Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .
    Tafolecimab
  • HY-106278
    GW 590735

    		PPAR Metabolic Disease
    GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC50=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .
    GW 590735
  • HY-P9928
    Alirocumab
    1 Publications Verification

    REGN 727; SAR 236553

    		 PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1 Cardiovascular Disease Cancer
    Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .
    Alirocumab
  • HY-161435
    PCSK9-IN-27

    		PCSK9 Metabolic Disease
    PCSK9-IN-27 (Compound 108) is a PCSK9 inhibitor (IC50: 3.4 nM). PCSK9-IN-27 reduces LDLR degradation and increases LDL-C uptake .
    PCSK9-IN-27
  • HY-106278A
    GW 590735 sodium

    		PPAR Metabolic Disease
    GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735 .
    GW 590735 sodium
  • HY-148626
    CVI-LM001

    		PCSK9 Metabolic Disease
    CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .
    CVI-LM001
  • HY-161942
    PCSK9-IN-31

    		PCSK9 Metabolic Disease
    PCSK9-IN-31 (Compound WX002) is an orally active PCSK9 inhibitor. PCSK9-IN-31 can lower low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in high cholesterol fed model rats .
    PCSK9-IN-31
  • HY-158827A
    AZD8233 sodium

    		PCSK9 Metabolic Disease
    AZD8233 sodium, a liver-targeting antisense oligonucleotide (ASO), inhibits subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 sodium increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.
    AZD8233 sodium
  • HY-128334
    PCSK9 modulator-2

    		PCSK9 Metabolic Disease
    PCSK9 modulator-2 (Compound 1) is a potent modulator of PCSK9 with an EC50 value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia .
    PCSK9 modulator-2
  • HY-146084
    PCSK9 modulator-3

    		PCSK9 Metabolic Disease
    PCSK9 modulator-3 (Compound 13) is a potent modulator of PCSK9 with an EC50 value of 2.46 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-3 has the potential for the research of hyperlipidemia .
    PCSK9 modulator-3
  • HY-146085
    PCSK9 modulator-4

    		PCSK9 Metabolic Disease
    PCSK9 modulator-4 (Compound 21) is a potent modulator of PCSK9 with an EC50 value of 0.15 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-4 has the potential for the research of hyperlipidemia .
    PCSK9 modulator-4
  • HY-158827
    AZD8233

    		PCSK9 Metabolic Disease
    AZD8233, a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.
    AZD8233
  • HY-P9928A
    Alirocumab (anti-PCSK9)
    1 Publications Verification

    REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)

    		 PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1 Cardiovascular Disease Cancer
    Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .
    Alirocumab (anti-PCSK9)
  • HY-153451
    PCSK9-IN-15

    		PCSK9 Metabolic Disease
    PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, KD <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia .
    PCSK9-IN-15
  • HY-109567
    Gemcabene

    PD-72953

    		 LDLR Metabolic Disease Inflammation/Immunology
    Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .
    Gemcabene
  • HY-B0144AS1
    Pitavastatin-d5 sodium

    NK-104-d5 sodium

    		 Apoptosis HMG-CoA Reductase (HMGCR) Mitophagy Autophagy Metabolic Disease Cancer
    Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
    Pitavastatin-d5 sodium
  • HY-115914
    Lipid-lowering agent-1

    		LDLR Others
    Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .
    Lipid-lowering agent-1
  • HY-109567A
    Gemcabene calcium

    PD-72953 calcium

    		 LDLR Metabolic Disease Inflammation/Immunology
    Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .
    Gemcabene calcium
  • HY-B0144A
    Pitavastatin

    NK-104

    		 HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
    Pitavastatin
  • HY-B0144B
    Pitavastatin sodium

    NK-104 sodium

    		 HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
    Pitavastatin sodium
  • HY-146398
    AMPK activator 6

    		AMPK Metabolic Disease
    AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .
    AMPK activator 6
  • HY-B0144S
    Pitavastatin-d4 hemicalcium

    NK-104-d4 hemicalcium; Pitavastatin-d4 hemicalcium

    		 Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis Metabolic Disease Cancer
    Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].
    Pitavastatin-d4 hemicalcium
  • HY-B0144
    Pitavastatin Calcium
    Maximum Cited Publications
    10 Publications Verification

    NK-104 hemicalcium; Pitavastatin hemicalcium

    		 HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
    Pitavastatin Calcium
  • HY-163436
    F44-A13

    		FXR Cytochrome P450 RAR/RXR PPAR ROR Metabolic Disease
    F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders .
    F44-A13
  • HY-159595
    PCSK9-IN-29

    		LDLR PCSK9 Metabolic Disease Inflammation/Immunology
    PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
    PCSK9-IN-29
  • HY-B0144R
    Pitavastatin (Calcium) (Standard)

    		HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Pitavastatin (Calcium) (Standard) is the analytical standard of Pitavastatin (Calcium). This product is intended for research and analytical applications. Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
    Pitavastatin (Calcium) (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: